GlassScriptPhysician profile
Allen Filiberti
NPI 1245263433
$4,323.91
in general payments reported to CMS, 2019-2025
24 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,855 · 2020: $413 · 2021: $210 · 2022: $442 · 2023: $530 · 2024: $519 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $987.83 | 2019-2025 | |
| Amgen INC. | $610.03 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $482.20 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $472.21 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.33 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $220.83 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $215.25 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $194.94 | 2019-2023 | Camzyos |
| Medtronic Vascular, INC. | $98.52 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $88.55 | 2019-2025 | |
| Boston Scientific Corporation | $84.56 | 2019-2025 | Avvigo Guidance System, Accolade Sr |
| Z-Medica, LLC | $81.03 | 2019-2020 | |
| Bardy Diagnostics, INC. | $80.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $77.85 | 2019 | |
| Amarin Pharma, INC. | $67.82 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $57.99 | 2023 | Uptravi |
| Regeneron Healthcare Solutions, INC. | $55.44 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $42.08 | 2024 | |
| Bridgebio Pharma, INC. | $28.80 | 2025 | Attruby |
| Vifor Pharma, INC. | $24.50 | 2019 | |
| Esperion Therapeutics, INC. | $20.77 | 2023 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $18.35 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $17.61 | 2024 | |
| Astellas Pharma US INC | $15.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Filiberti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.